Skip to main content
main-content

Head and neck cancer

21-10-2021 | Oncology | News | Article

Hearing loss protection recommendations made for paediatric CNS, head and neck cancer patients

The risk of high-frequency hearing loss in children undergoing cancer treatment to the central nervous system or the head and neck could be reduced by minimising doses of radiation to the cochlea and limiting cumulative doses of cisplatin or carboplatin, Canadian researchers say.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

14-10-2021 | Oncology | News | Article

Cancer surgery systems need strengthening against future societal lockdowns

Data form the international COVIDSurg collaborative study show that around one in seven patients did not undergo planned surgery for cancer if their region was in full COVID-19 lockdown.

30-01-2020 | Oncology | News | Article

Lenvatinib plus pembrolizumab shows promise for RCC and other solid tumors

Phase 1b/2 study data show that combining the multitargeted tyrosine kinase inhibitor lenvatinib with pembrolizumab could be a promising treatment option for patients with advanced renal cell carcinoma and selected other advanced solid tumor types.

Pills in hand

19-08-2019 | Oncology | News | Article

Early data show promise for the FGFR inhibitor rogaratinib

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

Male & female outlines_chalk

01-03-2019 | Oncology | News | Article

Sex disparity identified for hyperprogressive disease after immunotherapy

Women may be at greater risk than men for experiencing hyperprogression as a response to cancer treatment with immune checkpoint inhibitors, say researchers.

Hisham Mehanna

24-10-2018 | Head and neck cancer | Video

De-ESCALaTE HPV results revealed

Hisham Mehanna describes the results of the De-ESCALaTE HPV  trial comparing cetuximab versus cisplatin for the treatment of low-risk oropharyngeal cancer patients undergoing radiotherapy (5:43).